Navigation Links
Continued Uptake of Novartis/Incyte's Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market

BURLINGTON, Mass., Jan. 31, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2021, the continued uptake of Novartis/Incyte's recently launched JAK-2 inhibitor Jakafi (ruxolitinib) will be the greatest driver of growth in the myelofibrosis therapy market in the United States and Europe. Since only a small percentage of patients are eligible for allogeneic stem-cell transplantation—the lone curative treatment for myelofibrosis—the only care available for most patients is treatment of disease symptoms. According to interviewed experts, the entry of ruxolitinib is a significant advance in myelofibrosis treatment because they believe the drug offers clear improvements in constitutional symptoms and reduces the severe splenomegaly experienced by many patients, resulting in an overall better quality of life.


According to Niche Markets and Rare Diseases: Myelofibrosis, JAK-2 inhibition is the focus of considerable development activity in myelofibrosis and up to five new JAK-2 inhibitors could launch for the disease through 2021. Clinical trial data from long-term evaluation of myelofibrosis patients indicated that ruxolitinib improves overall survival in addition to providing sustained relief of constitutional symptoms—these recent analyses will likely accelerate uptake of ruxolitinib and other JAK-2 inhibitors.

"The most promising emerging JAK-2 inhibitor—YM Biosciences' CYT-387—has attracted interest from physicians because early phase trials have shown an effect on anemia in addition to an effect on constitutional symptoms," said Decision Resources Senior Vice President Cynthia Mundy , Ph.D. "Also, Gilead's recent decision to acquire YM Biosciences to gain access to the drug suggests Gilead expects CYT-387 to emerge as a formidable competitor to ruxolitinib and that this agent could capture substantial market share."

The report also finds that, although interviewed experts are enthusiastic about treatments that offer better management of myelofibrotic symptoms and improvements in quality of life, they indicate they are likely to continue using conventional treatment regimens in many of their patients, particularly those assessed as having lower risk. As a result, although ruxolitinib will experience significant adoption in the myelofibrosis market, hydroxyurea (Bristol-Myers Squibb's Hydrea, generics) will continue to be widely used to treat constitutional symptoms. Similarly, Celgene's emerging immunomodulator pomalidomide will not displace use of the older, related drugs—Celgene's Thalomid and Revlimid (lenolidomide).

About Myelofibrosis
Myelofibrosis is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kibow Biotech Marks Its Continued Growth with Relocation to Larger Facilities
2. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
3. Anoto Announces Continued Worldwide Expansion in Healthcare
4. Education and Collaboration Key to Continued Progress in Fighting Rogue Online Prescription Drug Sellers, Reports NABP
5. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
6. Lower Operating Expense Augments Digital X-rays Uptake Across Industries, Finds Frost & Sullivan
7. Endoscopy Devices Market to 2018 - Demand for Cost-Effective, Minimally Invasive Procedures and Reimbursement for New Indications to Increase Uptake
8. First Paralyzed Formula Race Car Drivers "Road to Indy" Sponsored By Coloplast
9. Safe Driving Prescription for Senior Drivers
10. Nedbank Golf Challenge a Driver for Breast Cancer in South Africa
11. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Post Your Comments:
(Date:10/2/2017)... announces the European launch of their new low volume, high throughput ... Cambridge, U.K on October 4th. The new ... unprecedented speed and sensitivity while using far less sample volume through ... ... ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate ... primary prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
Breaking Medicine News(10 mins):